ProCE Banner Activity

BTK Inhibitors for Mantle Cell Lymphoma: Overview and Current Treatment Landscape

Slideset

Download these slides for a brief overview of the initial data on the use of BTK inhibitors for patients with mantle cell lymphoma (MCL), with a focus on the mechanism of action, initial trial data in relapsed/refractory MCL, and important considerations for addressing adverse events associated with BTKi therapy and assessing individuals for adherence to BTKi regimens.

Released: December 05, 2024

Expiration: December 04, 2025

Share

Faculty

Brad Kahl

Brad Kahl, MD

Professor of Medicine
Washington University School of Medicine
Director, Lymphoma Program
Siteman Cancer Center
St. Louis, Missouri

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by an educational grant from AstraZeneca.

AstraZeneca